|Mr. Lars Fruergaard JÃ¸rgensen||Pres, CEO & Member of Management Board||N/A||N/A||1966|
|Mr. Karsten Munk Knudsen||Exec. VP, CFO & Member of the Management Board||N/A||N/A||1971|
|Dr. Mads Krogsgaard Thomsen||Exec. VP, Chief Science Officer & Member of the Management Board||N/A||N/A||1960|
|Mr. Henrik Ehlers Wulff||Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board||N/A||N/A||1970|
|Ms. Camilla Sylvest||Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board||N/A||N/A||1972|
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. It also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S’s ISS Governance QualityScore as of December 7, 2019 is 5. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 10; Compensation: 1.